Overview of the 2022 WHO classification of neuroendocrine neoplasms

G Rindi, O Mete, S Uccella, O Basturk, S La Rosa… - Endocrine …, 2022 - Springer
In this review, we detail the changes and the relevant features that are applied to neuroendocrine
neoplasms (NENs) in the 2022 WHO Classification of Endocrine and Neuroendocrine …

[HTML][HTML] Mixed adenoneuroendocrine carcinomas (MANECs) of the gastrointestinal tract: an update

S La Rosa, A Marando, F Sessa, C Capella - Cancers, 2012 - mdpi.com
The systematic application of immunohistochemical techniques to the study of tumors has led
to the recognition that neuroendocrine cells occur rather frequently in exocrine neoplasms …

Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms

S La Rosa, F Sessa, S Uccella - Endocrine pathology, 2016 - Springer
The wide application of immunohistochemistry to the study of tumors has led to the recognition
that epithelial neoplasms composed of both a neuroendocrine and nonneuroendocrine …

Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior

G Rindi, C Bordi, S Rappel, S La Rosa, M Stolte… - World journal of …, 1996 - Springer
The goal of this study was to provide information of prognostic value for gastric endocrine
tumors. A total of 205 gastric endocrine tumors have been studied: 193 well differentiated …

Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes

…, A Augello, A Vergani, S Dada, S La Rosa… - The journal of …, 2009 - journals.aai.org
Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC)
are presently underway without prior validation in a mouse model for the disease. In …

ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis

G Rindi, C Azzoni, S La Rosa, C Klersy, D Paolotti… - Gastroenterology, 1999 - Elsevier
Background & Aims: Gastric endocrine tumors show a wide spectrum of clinical behavior,
and prognostic assessement of individual tumors is difficult. The aims of this work were to …

[HTML][HTML] Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor …

M Volante, MP Brizzi, A Faggiano, S La Rosa, I Rapa… - Modern Pathology, 2007 - Elsevier
Typing somatostatin receptor expression in neuroendocrine tumors is of relevance to target
somatostatin analogue-based diagnostic approach and treatment. The expanding use of …

Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases

…, AM Krasinskas, E Vakiani, S La Rosa… - The American journal …, 2014 - journals.lww.com
Background: In the pancreas, poorly differentiated neuroendocrine carcinomas include small
cell carcinoma and large cell neuroendocrine carcinoma and are rare; data regarding their …

The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different …

…, F Sessa, E Solcia, C Capella, N Fazio, S La Rosa - …, 2016 - karger.com
Stefano La Rosa Stefano La RosaLa Rosa S, Sessa F: High-grade poorly differentiated
neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to …

Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms

S La Rosa, F Inzani, A Vanoli, C Klersy, L Dainese… - Human pathology, 2011 - Elsevier
Gastric neuroendocrine neoplasms differ considerably in histology, clinicopathologic
background, stage, and patient outcome, implying a wide spectrum of therapeutic options, hence …